ARISE-3 Phase 3 Clinical Trial of the RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTree

ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it has executed an agreement with Ora for the initiation of ARISE-3 to study the company’s new drug RGN-259 for the treatment of dry eye syndrome. ARISE-3 is a randomized, double masked, placebo controlled phase 3 clinical trial which is based entirely on the results of the company’s previous clinical trials, ARISE-1 and ARISE-2. ReGenTree said a total of 700 patients will be enrolled into the trial and the company expects the treatment will be completed in the first half of 2020.

ReGenTree is a U.S. joint venture company owned by GtreeBNT Co., and RegeneRx Biopharmaceuticals, specifically to develop RGN-259 in both the US and Canada for ophthalmic indications. ReGenTree licensed the rights to RGN-259 from RegeneRx in 2015. Thus far, ReGenTree has completed two phase 3 studies in the U.S. for dry eye which are ARISE-1 (Phase 2b/3) and ARISE-2 (Phase 3). In addition to dry eye, the company is currently conducting a Phase 3 study for neurotrophic keratopathy (NK), an orphan indication in ophthalmology. For additional information about ReGenTree, visit www.regentreellc.com.